Nucala nears new indication with nasal polyps data

3 April 2020

GlaxoSmithKline (LSE: GSK) has presented pivotal data on Nucala (mepolizumab) that supports a regulatory filing for an additional eosinophil-driven disease.

The UK’s largest pharma company has announced positive results from the SYNAPSE study of Nucala in patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP).

This is the first time an anti-interleukin (IL)5 biologic has reported positive Phase III data in CRSwNP, and adds to the range of eosinophil-driven diseases in which Nucala has efficacious data. The drug’s first approval came in 2015 for severe eosinophilic asthma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK